PIP4K-IN-a131

PIP4K-IN-a131 is PIP4K lipid kinases inhibitor, with IC 50 s of 1.9 µM and 0.6 µM for purified PIP4K2A and PIP4Ks, respectively. PIP4K-IN-a131 exhibits cancer-selective lethality via dual blockade of the lipid kinase PIP4Ks and mitotic pathways In Vitro PIP4K-IN-a131 (0-100 μM; 72 hours) is a potent antiproliferative agent with a clear selectivity toward cancer cells killing. PIP4K-IN-a131 eliminates cancer cells via a dual-inhibitory mechanism. PIP4K-IN-a131 causes inhibition of the PI3K/Akt/mTOR pathway only in normal BJ cells, but not in transformed counterparts. Inhibition of PIP4Ks by PIP4K-IN-a131 arrests normal cells at the G1/S phase of the cell cycle by suppressing the PI3K/Akt/mTOR signaling pathway via transcriptional upregulation of PIK3IP1. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: Normal and transformed BJ cells Concentration: 0-100 μM (MTT assay) Incubation Time: 72 hours Result: Selective killed cancer cells. RT-PCRCell Line: BJ cells Concentration: 5 µM Incubation Time: 24 hours Result: Induced the upregulation of PIK3IP1 mRNA levels. Form:Solid IC50& Target:IC50: 1.9 µM (PIP4K2A), 0.6 µM (PIP4Ks)

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet